The Uromigos

401 Folgen

1. Episode 323 ASCO24: TDXD in Bladder Cancer

   Vom: 2.6.2024
2. Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

   Vom: 2.6.2024
3. Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

   Vom: 1.6.2024
4. Episode 320: Team Canada's entry for the Uromigos Cup

   Vom: 25.5.2024
5. Episode 319: ASCO 2024: A Preview of GU Data

   Vom: 19.5.2024
6. Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

   Vom: 13.5.2024
7. Episode 317: AUA 2024 Preview with the AUA Secretary

   Vom: 1.5.2024
8. Episode 316: APCCC 2024 Summary with Silke Gillessen

   Vom: 28.4.2024
9. Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer

   Vom: 27.4.2024
10. Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer

    Vom: 27.4.2024
11. Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease

    Vom: 26.4.2024
12. Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer

    Vom: 26.4.2024
13. Episode 311: The Uromigos Paper of the Month - The POUT Trial

    Vom: 23.4.2024
14. Episode 310: Dosing and duration of drugs from a cost perspective

    Vom: 17.4.2024
15. Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer

    Vom: 7.4.2024
16. Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy

    Vom: 7.4.2024
17. Episode 307: Bladder-Sparing Approaches Part 2

    Vom: 2.4.2024
18. Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

    Vom: 28.3.2024
19. Episode 305: FDA and Oncology Clinical Trials

    Vom: 19.3.2024
20. Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

    Vom: 11.3.2024